Product Images Venlafaxine Hydrochloride

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 13 images provide visual information about the product associated with Venlafaxine Hydrochloride NDC 68084-713 by American Health Packaging, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

150 mg Blister

150 mg Blister

150 mg Carton

150 mg Carton

This is a pharmaceutical product, specifically Venlafaxine Hydrochloride Extended-Release Capsules USP. Each capsule contains 150mg of venlafaxine hydrochloride USP. The usual dosage is provided in the package insert. The drug should be stored between 20-25°C (66-77°F) with excursions permitted between 15-30°C (59-86°F). It is distributed by American Health Packaging and comes in a 100 capsule bottle. The accompanying medication guide should be dispensed with each bottle, and the product should be kept away from children. The product should not be used if the blister pack is damaged.*

37.5 mg Blister

37.5 mg Blister

37.5 mg Carton

37.5 mg Carton

This is a medication package for Venlafaxine Hydrochloride Extended-Release Capsules USP, containing 100 capsules (10x10) with each capsule having 375mg of Venlafaxine. The usual prescription dosage direction is indicated on the package insert. The package should be kept between 20°C to 25°C (68°F to 77°F), but excursions up to 30°C (86°F) are permitted. The medication should be kept away from the reach of children and should not be used if the package is damaged. The drug is from Aurobindo Pharma USA, Inc., and the package is distributed by American Health Packaging located in Columbus, Ohio.*

75 mg Blister

75 mg Blister

75 mg Carton

75 mg Carton

AHP69801

AHP69801

AHP70901

AHP70901

AHP71301

AHP71301

Figure 1

Figure 1

This is a description of a drug interaction with cimetane and the analyte Aniatxine, Vov, Veniatxine and Venistaxing. The recommendation is to use caution when using the drugs together as there may be an increase in PK Fold Change and 90% CI. It suggests monitoring blood pressure in patients who are at risk for hypertension, liver dysfunction, and geriatric patients. It also mentions that the clinical significance is unknown and that a dose adjustment may be necessary. There is no mention of a change relative to the reference value.*

Figure 2

Figure 2

Figure 3

Figure 3

Structure

Structure

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.